Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.39 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23794488 | 0.93 | IRAK4 (0.38) | RAD52KDM4ECXCR4CXCL12DPP7 | |
| SCHEMBL16098510 | 0.87 | CXCR4 (0.44) | RAD52KDM4ECXCR4CXCL12DPP7 | |
| SCHEMBL3411146 | 0.80 | GNAI3 (0.48) | RAD52DPP7IRAK4 | |
| SCHEMBL18479700 | 0.78 | IRAK4 (0.41) | KDM4EDPP7IRAK4ALDH1A1 | |
| SCHEMBL31177885 | 0.78 | IRAK4 (0.38) | DPP7IRAK4 | |
| SCHEMBL18342820 | 0.78 | OPRL1 (0.41) | DPP7IRAK4OPRL1 | |
| SCHEMBL3645463 | 0.77 | RAD52 (0.44) | RAD52KDM4ECXCR4CXCL12DPP7 | |
| SCHEMBL1779849 | 0.77 | RAD52 (0.56) | RAD52KDM4ECXCR4CXCL12DPP7 | |
| SCHEMBL455085 | 0.77 | RAD52 (0.56) | RAD52KDM4ECXCR4CXCL12DPP7 | |
| SCHEMBL1356297 | 0.76 | KDM4E (0.43) | RAD52KDM4ECXCR4CXCL12DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306111-A2 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-01-17 | — | — | EP | disclosed |
| EP-3452464-B1 | PYRAZOLE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USE THEREOF | HOFFMANN LA ROCHE (CH) | 2021-12-15 | — | — | EP | disclosed |
| EP-3200788-B1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME (US) | 2019-09-18 | — | — | EP | disclosed |
| CN-105209443-B | Indoleamine 2, 3-dioxygenase (IDO) inhibitors | 百时美施贵宝公司 | 2018-08-07 | — | — | CN | disclosed |
| EP-2970155-B1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) | BRISTOL MYERS SQUIBB CO (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9675571-B2 | Inhibitors of indoleamine 2,3-dioxygenase (IDO) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-13 | — | — | US | disclosed |
| WO-2016053769-A1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2016-04-07 | — | — | WO | disclosed |
| US-20160022619-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-28 | — | — | US | disclosed |
| EP-2970155-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-105209443-A | Indoleamine 2, 3-dioxygenase (IDO) inhibitors | BRISTOL MYERS SQUIBB CO | 2015-12-30 | — | — | CN | disclosed |
| WO-2014150677-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022619-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) | IDO1, IDO2, INMT | RAD52 3590/4885KDM4E 378/4885CXCR4 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.